Samsung Biologics, a contract development and manufacturing services provider (CDMO), has been recognised for the fourth consecutive year in the prestigious Dow Jones Sustainability World Index (DJSI). This accolade highlights the company’s ongoing commitment to integrating sustainable business practices throughout
Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has signed a series of manufacturing agreements with a European pharmaceutical company, valued at more than USD 668 million. The contracts will run until December 2031, contributing to the company’s
Samsung Biologics has been awarded the ISO 37301:2021 certification for Compliance Management Systems, recognising the company’s commitment to organisational governance and adherence to global regulatory standards. This new certification, presented by the British Standards Institution (BSI), underlines Samsung Biologics’ ongoing
Samsung Biologics, a global contract development and manufacturing organization (CDMO), has secured a $1.24 billion contract manufacturing agreement with an unnamed Asia-based pharmaceutical company. The deal, which runs until December 2037, is the largest contract ever signed by a single
Samsung Biologics has launched a new high-concentration formulation platform, S-HiCon, designed to support the development of high-dose biopharmaceuticals. The platform is aimed at improving formulation stability, reducing viscosity, and ensuring the efficacy of drugs with high concentration requirements. The platform
Samsung Biologics, a global contract development and manufacturing organisation (CDMO), announced its membership in the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. This marks the first time a Korean CDMO has joined the PSCI, a group dedicated to
Samsung Biologics Co Ltd (Samsung Biologics) provides contract manufacturing services for the production of biopharmaceuticals. The company offers discovery and development services, non-GMP DS and cGMP DS DP production services, clinical manufacturing services and biosafety and analytical testing services, among
Samsung Biologics, a Korean contract development and manufacturing organisation (CDMO), has announced a substantial manufacturing agreement with a large, unnamed U.S. drugmaker. The deal, valued at 1.46 trillion Korean won (approximately $1.05 billion), was disclosed on Tuesday and signifies a
UCB, the multinational biopharmaceutical company headquartered in Brussels, Belgium. and CDMO Samsung Biologics of South Korea have expanded their seven-year partnership with a new drug substance manufacturing deal worth 382 billion Korean won ($353 million). The partnership involves Samsung Biologics manufacturing several
Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has entered into a strategic partnership with LegoChem Biosciences, a biotech company at the forefront of the research and development of antibody-drug conjugate (ADC) programs. This partnership was announced on February 7,
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
